On September 27, 2018 Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, reported that the company is scheduled to present an update on the company’s programs and progress at several upcoming conferences (Press release, Trillium Therapeutics, 27 27, 2018, View Source [SID1234529627]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investor Conferences:

Ladenburg Thalmann 2018 Healthcare Conference
Presenter: Dr. Niclas Stiernholm, Chief Executive Officer
Date and Time: October 2, 2018 at 2:30 p.m. EDT
Location: Hotel Sofitel, New York City

Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology
Presenters: Dr. Niclas Stiernholm, Chief Executive Officer and Dr. Robert Uger, Chief Scientific Officer
Date and Time: October 3, 2018 at 4:00 p.m. EDT
Location: Lotte New York Palace Hotel, New York City

A live audio webcast of the Leerink Partners fireside chat will be available under the investor relations section of Trillium’s website at www.trilliumtherapeutics.com.